Vectical ointment approved for plaque psoriasis

VECTICAL (Calcitriol) 3micrograms/g ointment by Galderma
VECTICAL (Calcitriol) 3micrograms/g ointment by Galderma
Galderma Laboratories has received FDA approval for Vectical ointment (calcitriol 3mcg/g), a vitamin D3 product, for the treatment of mild-to-moderate plaque psoriasis in adults. This approval was based on two 8-week studies that compared Vectical ointment versus a vehicle treatment.  In the first study, improvements in mild-to-moderate plaque psoriasis severity began at week 2 and were sustained over the 8-week treatment period. By the end of the study, 34% of Vectical treated patients achieved treatment success versus 22% of those treated with vehicle.

Vectical ointment will be available by prescription in pharmacies in the first quarter of 2009.

For more information call (817) 961-5000 or visit www.vectical.com.